证券代码：688658 证券简称：悦康药业 公告编号：2025-027 悦康药业集团股份有限公司 公司控股股东京悦永顺持有的公司 26,500,000 股无限售流通股股票于 2025 年 5 月 27 日 10 时至 2025 年 5 月 28 日 10 时止（延时除外）在京东网司法拍卖 网络平台（网址：http://sifa.jd.com/29 户名：北京市第二中级人民法院）上进行 司法拍卖。具体内容详见公司于 2025 年 4 月 28 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于控股股东所持公司部分股份被司法拍卖的提示 性公告》（公告编号：2025-021）。 二、本次司法拍卖的进展情况 本次司法拍卖的京悦永顺持有公司的 26,500,000 股无限售流通股股票已于 2025 年 5 月 28 日 10 时结束拍卖。公司经查询京东网司法拍卖网络平台，显示 本次司法拍卖标的因在规定时间内无人出价已流拍。 关于控股股东所持公司部分股份被司法拍卖 流拍的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 ...

Core Viewpoint - The company announced that its controlling shareholder, Jingyue Yongshun, will auction 26.5 million unrestricted circulating shares, representing 5.88% of the total share capital and 14.70% of the shares held by the shareholder, on the JD.com judicial auction platform from May 27 to May 28, 2025. The auction failed due to no bids being placed, and this event will not have a significant adverse impact on the company's management or lead to changes in the controlling shareholder or actual controller [1]. Summary by Relevant Sections - Shareholder Information - Jingyue Yongshun holds 26.5 million shares, which is 5.88% of the total share capital [1] - This amount represents 14.70% of the shares held by the controlling shareholder [1] - Auction Details - The shares were scheduled for auction on JD.com from May 27 to May 28, 2025 [1] - The auction was unsuccessful as there were no bids placed [1] - Impact on Company - The failed auction will not significantly affect the company's management [1] - There will be no changes in the controlling shareholder or actual controller as a result of this event [1]

Core Viewpoint - The company, Yuekang Pharmaceutical, reported a decline in revenue for 2024, with total revenue of 3.781 billion yuan, a year-on-year decrease of 9.90% [1] Group 1: Operating Performance - The revenue breakdown shows that cardiovascular and anti-infection products generated 2.105 billion yuan and 789 million yuan, respectively, with declines of 20.73% and 22.67% [1][4] - The gross profit margin for the company was 58.76%, with significant differences among product categories; anti-infection products had a gross margin of 6.91%, while cardiovascular products had a margin of 91.08% [1][4] - The company provided a detailed table of sales revenue, volume, unit price, and year-on-year changes for different product types [2][3] Group 2: Revenue Analysis - The decline in cardiovascular product revenue was primarily due to a drop in sales of Ginkgo biloba extract injection, which saw an 8.47% decrease in volume and a reduction in average selling price [5] - The anti-infection product revenue decline was attributed to a shrinking market demand and increased competition, leading to lower sales volumes [5] - Conversely, the digestive system product revenue increased by 123.04% due to improved sales of omeprazole enteric-coated capsules, driven by enhanced marketing strategies [5] Group 3: Gross Margin Analysis - The gross margin differences among product types were influenced by drug classification and centralized procurement impacts [6][7] - Cardiovascular products maintained high margins due to effective market development and production cost management, while anti-infection products faced lower margins due to competitive pricing pressures [7] - The company’s gross margins were compared with industry peers, showing that its margins were generally in line with industry averages [8] Group 4: Sales and Marketing Expenses - The company reported a decrease in marketing and promotion expenses from 1.715 billion yuan in 2023 to 1.242 billion yuan in 2024, a reduction of 27.59% [10][11] - The decrease was attributed to the expansion of centralized procurement, which stabilized sales volumes in public medical institutions, leading to reduced promotional activities [11] - The company’s pricing strategy for major products considered various factors, including R&D costs, market demand, and competition [12] Group 5: Related Party Transactions - The company increased its purchases from Anhui Hengshun Information Technology Co., Ltd. to 221.678 million yuan in 2024, a significant increase from the previous year [18][20] - Anhui Hengshun primarily engages in the production and sale of various pharmaceutical intermediates, and the increase in purchases was due to expanded sales channels and cost advantages [19][20] - The procurement prices from Anhui Hengshun were found to be fair and competitive compared to other suppliers [21]

容诚会计师事务所（特殊普通合伙） 《关于悦康药业集团股份有限公司 2024 年年度报告问询函》回 复的报告 容诚专字[2025]200Z0694 号 上海证券交易所： 贵所于 2025 年 5 月 6 日向悦康药业集团股份有限公司（以下简称"公司" 或"悦康药业"）发出《关于悦康药业集团股份有限公司 2024 年年度报告的信 息披露监管问询函》（上证科创公函【2025】0091 号, 以下简称"问询函"）， 根据贵所出具的问询函的要求，容诚会计师事务所（特殊普通合伙）（以下简 称"本所"）作为悦康药业年审会计师，对问询函中需要会计师发表意见的事 项回复如下： 本回复中若出现总计数尾数与所列数值总和尾数不符的情况，均为四舍五 入所致。如无特别说明，本回复中使用的简称或名词释义与《悦康药业集团股 份有限公司 2024 年年度报告》一致。。 问题一：关于经营业绩 年报显示，公司 2024 年实现营业收入 37.81 亿元，同比下滑 9.90%，其中 心脑血管类、抗感染类分别实现收入 21.05 亿元和 7.89 亿元，同比下滑 20.73%、 22.67%；原料药、消化系统类分别实现收入 3.30 亿元、2.60 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-026 悦康药业集团股份有限公司 关于上海证券交易所 2024 年年度报告问询函的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"悦康药业"或"公司"）于 2025 年 5 月 6 日收到上海证券交易所出具的《关于悦康药业集团股份有限公司 2024 年年度报告的信息披露监管问询函》（上证科创公函【2025】0091 号以下简称 "问询函"）。公司会同容诚会计师事务所（特殊普通合伙）（以下简称"会计 师"），对问询函所列问题进行了认真核查并作出如下回复： 本回复中若出现总计数尾数与所列数值总和尾数不符的情况，均为四舍五 入所致。如无特别说明，本回复中使用的简称或名词释义与《悦康药业集团股 份有限公司 2024 年年度报告》一致。 问题一：关于经营业绩 单位：万元 主要产品名称 单位 2024 年度 2023 年度 销售收入 销量 销售收入 销量 心脑血管类 210,472.59 — 265,517.35 — 主要产 ...

Core Viewpoint - The article highlights the progress of Yuekang Pharmaceutical Group in developing innovative traditional Chinese medicine (TCM) products, emphasizing their commitment to high-quality drug development and the potential market opportunities for their new drugs [2][3][5]. Group 1: Product Development and Clinical Value - Yuekang Pharmaceutical is currently in the New Drug Application (NDA) review stage for three major products targeting cardiovascular, neurological, and respiratory diseases, showcasing the advantages of TCM's multi-target collaborative treatment [3][5]. - Clinical experts have expressed optimism about the three innovative drugs, with specific praise for the multi-target mechanism of Hydroxy Safflower Yellow A, which may improve long-term neurological function in acute ischemic stroke patients [3]. - The compound TCM Tongluo Jianbrain Tablets is noted for its effectiveness in treating vascular dementia, reflecting the TCM principle of addressing both symptoms and root causes [3][5]. Group 2: Market Position and Innovation - The pharmaceutical industry is transitioning from rapid growth to high-quality development, with innovation becoming the core driving force for companies to stand out [4][5]. - Yuekang Pharmaceutical is expected to solidify its industry-leading position through precise market understanding and continuous technological innovation [5]. Group 3: Internationalization and Digital Transformation - The Chinese biopharmaceutical industry is shifting towards high-quality development, with innovation and internationalization as key drivers [6]. - Yuekang Pharmaceutical has established a 500-member international R&D team and developed multiple core technology platforms, achieving significant patent breakthroughs [6][7]. - The company has partnered with Huawei for digital transformation, enhancing efficiency across various operational areas, including R&D and supply chain management [7][8]. Group 4: Commitment to Quality - The company emphasizes a strict quality control philosophy, ensuring high standards in every aspect of drug production, from raw materials to final products [2][3]. - Yuekang Pharmaceutical's commitment to quality is reflected in its extensive quality inspection center and rigorous production standards [2].

Core Viewpoint - Yuyuan Pharmaceutical Group emphasizes strict quality control in drug development, aiming for 100% quality assurance across all processes, from innovation to production [2] Group 1: Innovation and R&D - The company is establishing a leading domestic and international R&D technology system and industrialization platform, focusing on innovative drug development in various fields including traditional Chinese medicine and nucleic acid drugs [2] - Yuyuan has three products in the New Drug Application (NDA) review stage targeting unmet clinical needs: Hydroxy Safflower Yellow A for stroke, Tongluo Jianbrain Tablets for vascular dementia, and Zihua Wenfei Zhike Granules for post-infection cough [2][3] - The Hydroxy Safflower Yellow A drug aims to address the limitations of existing treatments for ischemic stroke, which has a high incidence in China, with over 2 million new cases annually [3][4] Group 2: Clinical Applications and Efficacy - Clinical trials for Hydroxy Safflower Yellow A have shown good efficacy and safety, with a purity of active ingredients raised to ≥95% [4] - Tongluo Jianbrain Tablets have demonstrated significant improvements in cognitive function and daily living abilities for patients with vascular dementia [4] - Zihua Wenfei Zhike Granules have shown superior cough relief compared to control groups, addressing common respiratory infections [5][6] Group 3: Strategic Development and Commercialization - The company is integrating artificial intelligence into its R&D processes to enhance precision and efficiency, significantly shortening development cycles and increasing success rates [6] - Yuyuan is focusing on creating a comprehensive commercialization strategy for its innovative drugs, including market positioning and insurance access [7] - The marketing strategy aims for core hospital coverage within six months post-launch and inclusion in provincial insurance directories within twelve months [7] Group 4: Digital Transformation - Yuyuan has partnered with Huawei for digital transformation, enhancing management systems and operational efficiency across various business domains [8] - The collaboration aims to improve the entire drug development process, from R&D to supply chain management, thereby increasing the efficiency of new drug launches [8] Group 5: Future Outlook - The company plans to leverage its three key products to solidify and expand its leading position in the pharmaceutical innovation sector, aiming for a transition from "excellence" to "superiority" in the industry [8]

Core Insights - Yuyuan Pharmaceutical Group is advancing three innovative drugs through the approval process, targeting significant medical needs [2] - The company emphasizes a comprehensive approach to drug development, integrating research, industrialization, and commercialization [2] Drug Development - The three drugs under review include Hydroxy Safflower Yellow A for acute ischemic stroke, Tongluo Jian Brain Tablets for vascular dementia, and Zihua Wenfei Zhiso Granules for post-infection cough [2] - These drugs aim to fill critical treatment gaps within their respective indications, with applications accepted by the National Medical Products Administration between February and March 2024 [2] Research and Development - Yuyuan Pharmaceutical has established 11 core technology platforms focusing on nucleic acid drugs, peptide drugs, cell and gene therapies, small molecule drugs, and specialty traditional Chinese medicine [3] - The company is currently developing 21 innovative drugs and holds 317 authorized patents, creating a differentiated competitive barrier [3] Marketing Strategy - The marketing strategy for innovative drugs includes enhancing tiered medical services, deepening grassroots engagement, and leveraging new retail channels for patient education [3] - The company aims for efficient service and support for partners through provincial marketing, ensuring broad coverage and strong management of product categories [3] Digital Transformation - Yuyuan Pharmaceutical has partnered with Huawei for digital transformation, becoming the first biopharmaceutical company to do so [3] - The collaboration focuses on innovation in research and development, smart factory construction, quality control, digital marketing, and supply chain management, achieving key results in management system upgrades and process restructuring [3]

Core Viewpoint - The Chinese pharmaceutical industry is undergoing a critical transformation, with innovation being essential for survival rather than a choice [2][3]. Company Summary - Yuyuan Pharmaceutical has shifted its focus from generic drugs to innovative research and development, especially since its listing on the STAR Market in 2020 [2]. - The company has established a comprehensive industrial layout with research centers in Beijing, innovation coordination in the Yangtze River Delta, a focus on high-end traditional Chinese medicine in the Greater Bay Area, and raw material supply in central China [2]. - Yuyuan Pharmaceutical aims to concentrate on major disease areas and increase R&D investment to promote the modernization and internationalization of traditional Chinese medicine [2]. - The company is currently in the NDA review stage for three key innovative products: Hydroxy Safflower Yellow A Injection, Tongluo Jian Nao Tablets, and Zihua Wenfei Zhiso Granules, and cannot disclose specific launch dates [2]. Industry Summary - The pharmaceutical industry is facing a complex external environment and increasing internal challenges, with structural and cyclical contradictions intertwining [3]. - According to the National Bureau of Statistics, the pharmaceutical manufacturing industry is expected to achieve approximately 2.53 trillion yuan in revenue in 2024, remaining flat year-on-year, which is 2.1 percentage points lower than the overall level of large-scale industrial enterprises [3]. - The total profit for the industry is projected to be 342.07 billion yuan in 2024, reflecting a year-on-year decline of 1.1% [3]. - The industry is in a significant transitional phase, moving from high-speed growth to high-quality development, with innovation being a long-term driving force [3]. - A report from Huayuan Securities indicates that 453 pharmaceutical companies are expected to generate 2.46 trillion yuan in revenue in 2024, a decrease of 0.55% year-on-year, and a net profit of 148.65 billion yuan, down 8.8% [4]. - In contrast, innovative drug companies are projected to achieve 47.53 billion yuan in revenue in 2024, marking a robust year-on-year growth of 68.4% [4].

Core Viewpoint - Yuekang Pharmaceutical emphasizes the philosophy that "the quality of medicine must be perfect; ninety-nine points equal zero," which is integral to its operations from research and development to production [1][4]. Group 1: Company Development - Yuekang Pharmaceutical started in 2001 in Beijing and has grown to be among the top 100 pharmaceutical companies in China, successfully listing on the Sci-Tech Innovation Board [1]. - The company aims to provide affordable quality medicine, overcoming challenges posed by imported drug monopolies and inconsistent drug quality in the market [1]. Group 2: Innovation and Quality Control - Yuekang has established a comprehensive quality system guided by clinical value, including a project for a national class innovative drug, which involves setting quality grading standards for medicinal materials [1]. - The company’s flagship product, Huoxin Wan, has undergone extensive clinical validation, showcasing a commitment to stringent raw material selection and post-market research [1]. Group 3: Production Standards - The production process for products like Omeprazole enteric-coated capsules involves over 200 inspections, ensuring high-quality standards that exceed national benchmarks [2]. - Yuekang has achieved certifications such as EU GMP and Japan JGMP, aligning its production standards with international practices and earning the title of "Quality Benchmark" in 2017 [2]. Group 4: Industry Positioning - Yuekang Pharmaceutical connects every node of the pharmaceutical supply chain through its commitment to quality, positioning itself as a pioneer in the international innovative pharmaceutical market [4].